Outlook therapeutics provides regulatory update on u.s. food and drug administration review of ons-5010/lytenava™ (bevacizumab-vikg) for the treatment of wet amd

Iselin, n.j., aug. 28, 2025 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the u.s. food and drug administration (fda) has issued a complete response letter (crl) to its biologics license application (bla) resubmission, indicating that the fda cannot approve the application in its present form for the treatment of wet age-related macular degeneration (wet amd).
AMD Ratings Summary
AMD Quant Ranking